BioSyent Inc. (TSXV: RX)

Market Cap	133.48M
Revenue (ttm)	34.51M
Net Income (ttm)	7.11M
Shares Out	11.37M
EPS (ttm)	0.60
PE Ratio	19.62
Forward PE	15.50
Dividend	0.18 (1.53%)
Ex-Dividend Date	Nov 29, 2024

Volume	2,953
Open	11.62
Previous Close	11.64
Day's Range	11.62 - 11.84
52-Week Range	8.24 - 12.13
Beta	0.93
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 14, 2025

About BioSyent

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: RX

Financial Performance

In 2023, BioSyent's revenue was 31.59 million, an increase of 13.12% compared to the previous year's 27.93 million. Earnings were 6.46 million, an increase of 18.35%.